Iloprost Zentiva (Iloprost)

Iloprost mimics the natural prostacyclin molecule, binding to IP receptors on pulmonary arterial smooth‑muscle cells. This activates adenylate cyclase, raises intracellular cAMP, causing vasodilation and inhibition of platelet aggregation, which together lower pulmonary vascular resistance.

The specific dose and infusion schedule of Iloprost Zentiva are determined by the prescribing clinician based on the patient’s condition, response, and tolerance. Dosage adjustments are made according to clinical guidelines and individual needs.

Safety data for Iloprost in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Iloprost belongs to the prostacyclin analog class, offering potent vasodilation and anti‑platelet effects. Compared with oral endothelin‑receptor antagonists or phosphodiesterase‑5 inhibitors, Iloprost provides rapid hemodynamic improvement but requires intravenous administration, which may affect convenience and monitoring requirements.

Iloprost Zentiva should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the solution in its original container until use, and discard any product that appears discolored or contains particles.

Iloprost Zentiva is supplied as a sterile solution for intravenous infusion. It is administered by a healthcare professional through a controlled infusion pump, following the dosing regimen prescribed by the treating physician.

Serious risks include severe hypotension, pulmonary edema, significant bleeding due to platelet inhibition, arrhythmias, and rare anaphylactic reactions. Patients should be monitored closely for these events, especially during the initial dosing period.

Iloprost is contraindicated in patients with known hypersensitivity to iloprost or any component of the formulation, those with recent myocardial infarction, uncontrolled severe hypotension, or active bleeding disorders. Clinicians must evaluate each patient’s medical history before initiating therapy.